top of page

Apellis Pharmaceuticals: Developing Life-Changing Therapies

Apellis Pharmaceuticals is a global biopharmaceutical company that is committed to developing life-changing therapies for some of the most challenging diseases patients face. The company combines courageous science and compassion to create innovative solutions for patients worldwide. Their focus on developing therapies to target C3 has seen them lead the way in complement medicine, with two approved medicines targeting C3.

Pegcetacoplan

Pegcetacoplan (APL-2) is an investigational, targeted C3 therapy designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. The drug is being developed for the treatment of several complement-driven diseases, including paroxysmal nocturnal hemoglobinuria (PNH), immune complex membranoproliferative glomerulonephritis (IC-MPGN), and C3 glomerulopathy (C3G).

Apellis announced in 2022 that the FDA had granted Fast Track designation to pegcetacoplan for the treatment of PNH. The company is currently conducting a Phase 3 trial of pegcetacoplan for the treatment of PNH, with interim results expected in the first half of 2023.

APL-9

APL-9 is an investigational, subcutaneously administered complement C3 inhibitor. The drug is being developed as a treatment for several indications, including geographic atrophy (GA), a leading cause of blindness worldwide. Apellis is currently conducting a Phase 2b trial of APL-9 for the treatment of GA.

APL-8

APL-8 is an investigational drug designed to inhibit C3 activation and deposition on the surface of red blood cells (RBCs). The drug is being developed for the treatment of complement-mediated hemolytic anemias, including cold agglutinin disease (CAD) and paroxysmal cold hemoglobinuria (PCH).

Apellis is currently conducting a Phase 2 trial of APL-8 for the treatment of CAD and PCH.

Equity Awards

Apellis Pharmaceuticals recently announced that the company had approved the grant of equity awards to 13 new employees. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4) as equity inducement awards outside of the company's 2017 Stock Incentive Plan.

The employees received options to purchase 28,560 restricted stock units (RSUs). Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter, subject to each employee's continued employment on each vesting date.

About Apellis

Apellis Pharmaceuticals is a global biopharmaceutical company that is committed to developing life-changing therapies for some of the most challenging diseases patients face. The company's focus on complement-mediated diseases has seen them lead the way in complement medicine, with two approved medicines targeting C3.

Apellis combines courageous science and compassion to create solutions that improve the lives of patients worldwide. With nearly a dozen clinical and pre-clinical programs underway, the company believes that they have only begun to unlock the potential of targeting C3 across many serious diseases.

Apellis Forward-Looking Statement

Apellis Pharmaceuticals has issued a forward-looking statement, stating that any statements about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. The company emphasizes that actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, as discussed in the "Risk Factors" section of Apellis' Annual Report on Form 10-K with the Securities and Exchange Commission on February 21, 2023.

Conclusion

Apellis Pharmaceuticals is a leading biopharmaceutical company that is committed to developing life-changing therapies for some of the most challenging diseases patients face. The company's focus on complement-mediated diseases has seen them lead the way in complement medicine, with two approved medicines targeting C3. With several clinical and pre-clinical programs underway, Apellis is poised to unlock the potential of targeting C3 across many serious diseases, ultimately improving the lives of patients worldwide.

9 views

Recent Posts

See All

Catalpol: A Potential Treatment for Diabetic Nephropathy

Introduction Diabetic nephropathy (DN) is a common complication of diabetes, characterized by abnormal angiogenesis of glomerular endothelial cells (GECs) and macrophage infiltration Galectin-3, a pr

Comentários


bottom of page